{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:25:57Z","timestamp":1793784357387,"version":"4.6.1"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Medical Sciences"],"abstract":"<jats:p>Background\/aim: This study aimed to investigate the relationship between the presence of BRAF, HRAS, NRAS, and KRAS gene mutations and the development of dedifferentiation (iodine-refractory disease) and extrathyroidal disease in patients with differentiated thyroid carcinoma (DTC).Materials and methods: Seventy-seven adult patients classified as intermediate and high-risk according to the ATA 2015 guidelines, who underwent total thyroidectomy followed by radioiodine I-131(RAI) therapy between June 2014 and December 2022, were included. Clinical data were collected via the hospital information system, including the number of surgeries, RAI treatments, and levels of thyroglobulin(Tg), anti-thyroglobulin, and thyroid-stimulating hormone. Histopathological subtypes of DTC were re-evaluated, and mutation analyses of BRAF, KRAS, NRAS, and HRAS genes were performed using real-time polymerase chain reaction (PCR). Statistical analyses were conducted using Medcalc software, with p-values &lt;0.05 considered significant.Results: Of the 77 patients, most had classical papillary thyroid carcinoma, while others represented various subtypes. No mutations were found in BRAF K601E\/V600_K601, KRAS G12x-G13D, or NRAS G12-G13; however, NRAS Q61x was found in one patient, HRAS Q61x in 12, and BRAFV600E\/Ec in 36. A significant relationship was observed between HRAS Q61x mutation and disease response, alongside a significant association between gene mutations and iodine-refractory disease development (p=0.0004). ROC curve analysis indicated a 49.2 ng\/ml threshold for Tg with 75% sensitivity and 94.1% specificity.Conclusion: Our findings suggest that the HRAS Q61x gene mutation is significantly associated with iodine-resistant disease and may serve as a prognostic biomarker in early-stage thyroid cancer and aid in disease monitoring in metastatic patients.<\/jats:p>","DOI":"10.55730\/1300-0144.5944","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:43:13Z","timestamp":1740483793000},"page":"72-81","source":"Crossref","is-referenced-by-count":2,"title":["Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective"],"prefix":"10.55730","volume":"55","author":[{"given":"HAL\u0130M","family":"\u00d6Z\u00c7EV\u0130K","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00dcGE \u00d6NER","family":"TAMAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00dcND\u00dcZALP BU\u011eRAHAN","family":"BABACAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SELMA","family":"\u015eENG\u0130Z ERHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MERVE NUR","family":"ACAR TAYYAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u0130RAY","family":"ERT\u00dcRK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2025,2,18]]},"container-title":["Turkish Journal of Medical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:29:16Z","timestamp":1793780956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol55\/iss1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0144.5944","relation":{},"ISSN":["1300-0144"],"issn-type":[{"value":"1300-0144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}